Results 81 to 90 of about 26,068 (276)

Hypertension: Renin-Angiotensin-Aldosterone System Alterations [PDF]

, 2015
Blockers of the renin-angiotensin-aldosterone system (RAAS), that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the ...
Danser, A.H.J. (Jan), Esch, J.H.M. (Joep) van, Meiracker, A.H. (Anton) van den, Riet, L. (Luuk) te, Roks, A.J.M. (Anton)   +4 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Pharmacotherapy of resistant arterial hypertension [PDF]

Терапевтический архив, 2018
Pharmacotherapy of resistant arterial hypertension represents a serious problem, because today there are no clear algorithms of action in this clinical situation. The review discusses the key works in which the authors propose a solution to this problem.
N E Shepeleva, A V Rodionov, V V Fomin
doaj   +3 more sources

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. [PDF]

, 2018
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard end-points ...
Acker, Alfonzo, An, Anker, Bakris, Beusekamp, Bozkurt, Chang, Chen, Clausen, Cooper, Desai, Dittrich, Einhorn, Elliott, Epstein, Epstein, Epstein, Eschalier, Ingelfinger, Jain, Kamel, Kayexalate (sodium polystyrene) [package insert], Khanagavi, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, Kjeldsen, Komajda, Lund, Luo, Maggioni, Mancia, Mathialahan, Mattu, McCullough, Molnar, Montalescot, National Institute for Health and Care Excellence (NICE), Packham, Palmer, Perazella, Pitt, Pitt, Pitt, Pitt, Pitt, Ponikowski, Poole-Wilson, Raebel, Ramadan, Rastegar, Rossignol, Rossignol, Rydén, Sarafidis, Shah, Sterns, Takaichi, Tamargo, Tamargo, UK Renal Association, Vardeny, Vardeny, Wei, Weir, Weir, Weir, Weisberg   +66 more
core   +2 more sources

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT

Российский кардиологический журнал, 2015
The review takes into consideration the novel data on heart failure treatment: application of mineralocorticoid antagonists. The pathogenetic points are highlighted that are proved by clinical trials, as epidemiological concerns. Further opportunites are
V. N. Soboleva, E. O. Taratukhin
doaj   +1 more source

Molecular, Cellular, and Clinical Evidence That Sodium‐Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.
Milton Packer
doaj   +1 more source

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18:Nuclear hormone receptors [PDF]

, 2017
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and ...
,, Alexander, Stephen Ph, Cidlowski, John A, Davies, Jamie A, Faccenda, Elena, Harding, Simon D, Kelly, Eamonn, Marrion, Neil V, Pawson, Adam J, Peters, John A, Sharman, Joanna L, Southan, Christopher   +11 more
core   +5 more sources

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Alterations in vascular function in primary aldosteronism - a cardiovascular magnetic resonance imaging study [PDF]

, 2014
Introduction: Excess aldosterone is associated with increased cardiovascular risk. Aldosterone has a permissive effect on vascular fibrosis. Cardiovascular magnetic resonance imaging (CMR) allows study of vascular function by measuring aortic ...
A McCurley, A Rudolph, A Tomaschitz, B Fink, B Strauch, B Strauch, C Catena, C Delles, C Delles, CB Stehr, D Rizzoni, DA Calhoun, E M Freel, E P McQuarrie, EM Freel, G Bernini, GE Callera, GF Mitchell, GP Rossi, JM Connell, JW Funder, K Gaddam, L U Zimmerli, LU Zimmerli, MJ van Trijp, MR Robinson, NC Edwards, OJ Rider, OJ Rider, P B Mark, P Milliez, P Rerkpattanapipat, PB Mark, R Holaj, R Rocha, RB Stacey, S Boyle, S Laurent, T Indra, WJ Rogers, YH Lin   +40 more
core   +1 more source